Tag: CRS

Immunotherapy Web Featured Images 103

SITC clinical practice guideline on immune effector cell-related adverse events

The SITC convened a panel to discuss the recognition and management of common toxicities in the context of IEC treatment, including baseline laboratory parameters for monitoring, timing to onset, and pharmacological interventions, ultimately forming evidence- and consensus-based recommendations to assist medical professionals in decision-making and to improve outcomes for patients.

Visit website
Immunotherapy Web Featured Images 82

Recommendations for screening, monitoring, prevention, and prophylaxis of infect...

Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene ciloleucel and tisagenlecleucel) have been approved for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia; many other CAR-T constructs are in research for both hematological and non-hematological diseases.

Visit website